CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Regulation FD Disclosure

CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Regulation FD Disclosure

Story continues below

ITEM 7.01. REGULATION FD DISCLOSURE.

On May 9, 2017, the Company issued a press release entitled
“Chembio Diagnostics Reports First Quarter 2017 Financial
Results”. A copy of the press release is furnished herewith as
Exhibit 99.1
On May 9, 2017, the Company posted a PowerPoint Presentation to
their website entitled “Investor Presentation May, 2017.” A
copy of the presentation is furnished herewith as Exhibit 99.2.
In addition, also on May 9, 2017, the Company posted an Investor
Fact Sheet to their website. A copy of the fact sheet is
furnished herewith as Exhibit 99.3
The information in this Item 7.01 of this Form 8-K is being
furnished and shall not be deemed “filed” for the purposes of
Section 18 of the Securities Exchange Act of 1934, or otherwise
subject to the liabilities of that section. The information in
this Item 7.01 of this Form 8-K also shall not be deemed to be
incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Securities Exchange Act of 1934,
except to the extent that the Company specifically incorporates
it by reference.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
Exhibit Number
Description
99.1
Press Release entitled “Chembio Diagnostics Reports First
Quarter 2017 Financial Results” dated May 9, 2017
99.2
Presentation entitled “Investor Presentation May 2017”
dated May 9, 2017
99.3
Investor Fact Sheet posted to the company website dated May
9, 2017


About CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI)

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company’s product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.

CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Recent Trading Information

CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) closed its last trading session down -0.05 at 6.65 with 11,587 shares trading hands.

An ad to help with our costs